Fortfahren mit
Über diesen Artikel
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
SMILES string
NC1=N[C@@](C2=CC=CC(C3=CN=CN=C3)=C2)(C4=CC(C(F)F)=NC=C4)C5=CC=CC(F)=C51
InChI
1S/C24H16F3N5/c25-19-6-2-5-18-21(19)23(28)32-24(18,17-7-8-31-20(10-17)22(26)27)16-4-1-3-14(9-16)15-11-29-13-30-12-15/h1-13,22H,(H2,28,32)/t24-/m0/s1
InChI key
MRXBCEQZNKUUIP-DEOSSOPVSA-N
Biochem/physiol Actions
1 of 1
Dieser Artikel | |||
|---|---|---|---|
| form powder | form powder | form powder | form powder |
| assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay ≥98% (HPLC) |
| storage temp. −20°C | storage temp. −20°C | storage temp. 2-8°C | storage temp. −20°C |
| solubility DMSO: 2 mg/mL, clear | solubility DMSO: 2 mg/mL, clear | solubility DMSO: 30 mg/mL, clear | solubility DMSO: 2 mg/mL, clear |
| color white to beige | color white to beige | color white to beige | color white to beige |
AZD3839 (S)-1-[2-(Difluoromethyl)pyridin-4-yl] research applications | AZD3463 1356962-20-3 CAS number, AZD3463 ALK inhibitor research product, AZD3463 IGF1R inhibitor for cancer studies, AZD3463 N-(4-(4-Amino-1-piperidinyl)-2-methoxyphenyl)-5-chloro-4-(1H-indol-3-yl)-2-pyrimidinamine, AZD3463 cancer therapy reagent, AZD3463 chemical structure N-(4-(4-Aminopiperidin-1-yl)-2-methoxyphenyl)-5-chloro-4-(1H-indol-3-yl)pyrimidin-2-amine, AZD3463 for FLT3-ITD-dependent acute myeloid leukemia, AZD3463 for cancer research, AZD3463 for crizotinib-resistant cancer, AZD3463 oral availability cancer treatment, AZD3463 potency IC50 15-21 nM, AZD3463 procurement for laboratory use, AZD3463 receptor tyrosine kinase inhibitor, AZD3463 research grade inhibitor, Sigma-Aldrich AZD3463 for neuroblastoma | - | - |
Lagerklasse
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.



